Since it is known that EGFR expression is high in most cells in patients with oral cancer, and only a few mutation would be observed in BRAF and RAS [19], which are key intracellular signaling molecules, it is not necessary to confirm expression of EGFR and the absence of BRAF and RAS mutations to use C-mab, unlike the cases of colorectal cancer. This evidence concerns the gene EGFR and colorectal cancer.